Here’s what you need to know:
1. The company is developing an antibiotic gel to treat prosthetic joint infections.
2. The injectable gel conforms to an implant or surgical surface, where it releases the antibiotic drug before dissolving.
3. Sonoran Biosciences cofounder and chief scientific officer Derek Overstreet told the Phoenix Business Journal that he hopes this antibiotic treatment will help patients avoid additional surgeries.
4. The grant, awarded by the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases, will fund Sonoran Biosciences’ next research phase for the gel.
More articles on orthopedics:
Study finds cost-effective outpatient total shoulder arthroplasty as safe as inpatient: 5 insights
Connecticut Orthopaedic Specialists provides $250k for Quinnipiac University: 4 key points
Study finds gaps in orthopedic trauma at Houston’s hospital system: 5 insights
